《市評》恆指失兩萬四 阿里走弱 藥股及周傑倫概念股受捧
美國總統特朗普稱擬對銅進口徵收50%關稅及對進口藥品徵收高達200%關稅,港股今日向下。美國總統特朗普週二強調不會對8月1日關稅截止日期有任何寬限,美股道指及納指隔晚各跌0.4%及升0.03%,撰文之時,美國2年期債券孳息跌至3.897%,美國10年期債券孳息跌至4.399%,美匯指數升0.06%至97.57,道指期貨最新升21點或0.05%,納指期貨最新跌5點或0.03%。中國公佈6月CPI按年轉升0.1%(市場預測跌0.1%),6月PPI按年跌3.6%(市場預測跌3.2%),上證綜指全日跌4點或0.13%收3,493點,深證成指跌0.06%,滬深兩市成交額共1.51萬億元人民幣。
恆指低開86點後跌幅擴大,曾跌320點一度低見23,827點,全日跌255點或1.1%,收23,892點;國指跌111點或1.3%,收8,597點;恆生科技指數跌93點或1.8%,收5,231點。大市全日成交總額2,338.78億元。北水交易總成交額1,326.54億元,而南向資金今日淨流入92.56億元(上日淨流入3.87億元)。新股方面,藍思科技(06613.HK)收報19.84元,較上市價18.18元高9.1%。
國泰君安國際(01788.HK)股價回吐5.3%,成交121.1億元。香港中旅(00308.HK)抽高19.9%,成交逾26.4億元。官方認證周傑倫入駐抖音平臺,內媒報道歌手周傑倫入駐抖音15分鐘漲粉5萬,周傑倫概念股炒上,巨星傳奇(06683.HK)飆94.4%,成交114.85億元。此外,恆地(00012.HK)建議發行80億元2030年到期CB,每股換股價36元,該股下滑8.6%報25.9元。
【巨星傳奇飆 阿里美團弱】
阿里(09988.HK)全日股價下滑3.8%收102.9元,成交額139.5億元,京東(09618.HK)走低1.9%,美團(03690.HK)跌2.5%,而快手(01024.HK)走低2.3%。內媒報道,淘寶閃購於上週三(2日)正式啓動總額高達500億元人民幣的補貼計劃。一週過去,最新數據顯示,在大消費場景帶動下,4,124個餐飲品牌生意突破歷史高位,2,318個非餐飲品類訂單量翻倍。
瑞銀髮表報告指,內地互聯網行業即時零售競爭正迅速升溫,各大平臺補貼持續升級,阿里旗下淘寶閃購宣佈在未來12個月投入500億元人民幣,京東旗下京東外賣亦額外投入100億元人民幣以支持優質商家。美團旗下美團優選則收縮虧損地區佈局,以聚焦核心業務發展。該行預期,今年中國即時零售(撇除外賣)潛在市場規模可達到7,600億元人民幣,按年增長30%,總額佔電商市場的約4%至5%。雖然加碼拓展即時零售業務,各大電商平臺將可創造交叉銷售機會,但計及投資額瑞銀預期短期內將令企業盈利預測下調,相信當前競爭形勢至少會持續至今年雙11,競爭壓力加大將令京東、美團及阿里未來數月股價表現可能受壓。
【跌股一千隻 醫藥股搶高】
港股今日市寬轉弱,主板股票的升跌比率爲22比25(上日爲29比18),下跌股份1,028只(跌幅2.2%),恆指成份股今日23只股份上升,下跌股62只,升跌比率爲27比73(上日65比33)。大市今日錄沽空305.58億元,佔可沽空股份成交額2,052.68億元的14.887%(上日爲14.167%)。
美國總統特朗普擬對銅進口徵收50%關稅,江銅(00358.HK)高開3.5%後倒跌,全日跌3.5%。五礦資源(01208.HK)及洛鉬(03993.HK)跌4.4%及4.7%。花旗指美國對銅徵收50%關稅令進口需求銳減,料未來三個月國際銅價回落至每噸8,800美元。
醫藥股抽高,中生製藥(01177.HK)抽升10.1%,爲升幅最大藍籌股,翰森製藥(03692.HK)及石藥(01093.HK)股價上揚4.2%及2.9%,恆瑞醫藥(01276.HK)兩款藥物獲準進行臨牀測試,股價抽高15.6%。
高盛發表報告,中國生物科技企業的產品出海授權趨勢推動上半年股價表現強勁(今年以來股價已累升78%,相較中國離岸及在岸醫療保健股各累升41%及2%(對比MSCI中國指數累升18%),近期市場對交易持續性及估值可持續性的討論開始浮現。該行認爲經過對授權交易及中國創新藥管線在全球背景下的深入分析,該行認爲這是一場結構性轉變,而非短暫反彈。該行指,產品授權、併購及新公司設立的成熟路徑將進一步釋放上行潛力:1)截至2025年中期,中國約佔全球臨牀試驗管線的三分之一,及上半年進入人體研究的創新藥候選物約佔50%;2)在可能定義未來標準治療的新型療法中,中國企業在ADC(抗體藥物複合體)、BsAb/TCE等領域主導管線,或在siRNA(小分子幹擾核糖核酸)、PROTAC(蛋白降解靶向嵌合體)等領域成爲重要新興參與者;3)全球社羣對中國數據的關注度增加,中國至全球數據的轉化性也在改善。該行維持中生製藥「買入」評級,目標價由3.92元上調至6.19元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.